We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01509911
Recruitment Status : Unknown
Verified February 2016 by Tiltan Pharma Ltd..
Recruitment status was:  Active, not recruiting
First Posted : January 13, 2012
Last Update Posted : February 5, 2016
Sponsor:
Collaborators:
Technostat
Novatrials
Information provided by (Responsible Party):
Tiltan Pharma Ltd.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Unknown
  Estimated Primary Completion Date : October 2016
  Estimated Study Completion Date : January 2017